Increased expression of ACTH (MC2R) and androgen (AR) receptors in giant bilateral myelolipomas from patients with congenital adrenal hyperplasia

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP ALMEIDA, Madson Q. FMUSP-HC
MONTE, Osmar
DENES, Francisco T. FMUSP-HC
BACHEGA, Tania A. S. S. FMUSP-HC 2014
dc.identifier.citation BMC ENDOCRINE DISORDERS, v.14, article ID 42, 5p, 2014
dc.identifier.issn 1472-6823
dc.description.abstract Background: Although chronic adrenocorticotropic hormone (ACTH) and androgen hyperstimulation are assumed to be involved in the pathogenesis of adrenal myelolipomas associated with poor-compliance patients with congenital adrenal hyperplasia (CAH), the expression of their receptors has not yet been demonstrated in these tumors so far. Methods: We analyzed Melanocortin 2 receptor (MC2R), Androgen Receptor (AR), Leptin (LEP), and Steroidogenic factor 1 (SF1) expression using real-time qRT-PCR in two giant bilateral adrenal myelolipomas from two untreated simple virilizing CAH cases and in two sporadic adrenal myelolipomas. In addition, the X-chromosome inactivation pattern and CAG repeat numbers in AR exon 1 gene were evaluated in the 4 cases. Results: The MC2R gene was overexpressed in myelolipomas from 3 out of 4 patients. AR overexpression was detected in 2 tumors: a giant bilateral myelolipoma in a CAH patient and a sporadic case. Simultaneous overexpression of AR and MC2R genes was found in two of the cases. Interestingly, the bilateral giant myelolipoma associated with CAH that had high androgen and ACTH levels but lacked MC2R and AR overexpression presented a significantly shorter AR allele compared with other tumors. In addition, X-chromosome inactivation pattern analysis showed a polyclonal origin in all tumors, suggesting a stimulatory effect as the trigger for tumor development. Conclusion: These findings are the first evidence for MC2R or AR overexpression in giant bilateral myelolipomas from poor-compliance CAH patients.
dc.language.iso eng
dc.relation.ispartof BMC Endocrine Disorders
dc.rights openAccess
dc.subject Adrenal myelolipoma; Congenital adrenal hyperplasia; ACTH; MC2R; Androgen receptor; Clonality analysis
dc.subject.other 21-hydroxylase deficiency; cag repeats; gene; diagnosis; cancer
dc.title Increased expression of ACTH (MC2R) and androgen (AR) receptors in giant bilateral myelolipomas from patients with congenital adrenal hyperplasia
dc.type article
dc.rights.holder Copyright BIOMED CENTRAL LTD LIM/42 LIM/55
dc.identifier.doi 10.1186/1472-6823-14-42
dc.identifier.pmid 24884994
dc.type.category original article
dc.type.version publishedVersion ALMEIDA, Madson Q.:HC:LIM/42 KAUPERT, Laura C.:FM: BRITO, Luciana P.:HC:LIM/42 LERARIO, Antonio M.:HC:LIM/42 MARIANI, Beatriz M. P.:FM: DENES, Francisco T.:HC:LIM/55 MENDONCA, Berenice B.:FM:MCM BACHEGA, Tania A. S. S.:FM:MCM · RIBEIRO, Marta:Fac Ciencias Med Santa Casa Misericordia Sao Paul, Dept Clin Med, Unidade Endocrinol & Metab, Sao Paulo, Brazil
· MONTE, Osmar:Fac Ciencias Med Santa Casa Misericordia Sao Paul, Dept Clin Med, Unidade Endocrinol & Metab, Sao Paulo, Brazil 2-s2.0-84900852609 WOS:000336057600001 LONDON ENGLAND
hcfmusp.relation.reference · Dean G, 1971, Scott Med J, V16, P513
· German-Mena E, 2011, ENDOCR PRACT, V17, P441, DOI 10.4158/EP10340.RA
· Gururajan M, 2012, TRANSL ANDROL UROL, V1, P19
· Hagiwara H, 2008, ENDOCR PATHOL, V19, P122, DOI 10.1007/s12022-008-9034-2
· Hisamatsu H, 2004, INT J UROL, V11, P416, DOI 10.1111/j.1442-2042.2004.00815.x
· Ioannidis O, 2011, PATHOL ONCOL RES, V17, P775, DOI 10.1007/s12253-010-9330-2
· Kaupert LC, 2010, HORM RES PAEDIAT, V73, P238, DOI 10.1159/000284387
· Kim SC, 2006, INT J GYNECOL CANCER, V16, P190, DOI 10.1111/j.1525-1438.2006.00300.x
· Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
· Mansmann G, 2004, ENDOCR REV, V25, P309, DOI 10.1210/er.2002-0031
· MASCHLER I, 1979, CLIN ENDOCRINOL, V10, P493, DOI 10.1111/j.1365-2265.1979.tb02106.x
· McGeoch SC, 2012, J CLIN ENDOCR METAB, V97, P343, DOI 10.1210/jc.2011-2373
· Mermejo LM, 2010, ARQ BRAS ENDOCRINOL, V54, P419, DOI 10.1590/S0004-27302010000400012
· Nermoen I, 2011, CLIN ENDOCRINOL, V75, P753, DOI 10.1111/j.1365-2265.2011.04151.x
· PLAUT A, 1958, AM J PATHOL, V34, P487
· Rocha RO, 2008, CLIN ENDOCRINOL, V68, P226, DOI 10.1111/j.1365-2265.2007.03023.x
· SELYE H, 1950, AM J PATHOL, V26, P211
· Wu MH, 2008, EUR J CANCER PREV, V17, P317, DOI 10.1097/CEJ.0b013e3282f75e7f
dc.description.index PubMed
hcfmusp.citation.scopus 9
hcfmusp.citation.wos 10 Brasil

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account